FDA Clearance Tracker · K214022
Accu-Chek Softclix Blood Lancing System
Last checked: Nov 19, 2026Latest source record: Feb 17, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Feb 17, 2022
Substantially Equivalent
Time to decision
57 days
Received Dec 22, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K214022
- Device name
- Accu-Chek Softclix Blood Lancing System
- Applicant
- Roche Diabetes Care, Inc.
- Applicant location
- Indianapolis, IN
- Received
- Dec 22, 2021
- Decided
- Feb 17, 2022
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 878.4850
- Specialty
- General & Plastic Surgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QRL (Multiple Use Blood Lancet For Single Patient Use Only).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K214022
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Roche Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K232488 · Decided Nov 13, 2023 · 88 days after receipt
Device type: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature (FMK) · General & Plastic Surgery
K232509 · Decided Nov 13, 2023 · 87 days after receipt
Device type: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature (FMK) · General & Plastic Surgery
K220849 · Decided May 19, 2022 · 57 days after receipt
Device type: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature (FMK) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.